Isavuconazole Shows Favorable Liver Safety Signal in Antifungal Analysis
In a FAERS analysis, isavuconazole had the weakest hepatobiliary adverse-event reporting signal among five azole antifungals, lower than voriconazole and posaconazole. Even so, all five agents showed notable liver-related reporting signals, leading researchers to advise liver function monitoring for any azole. Separately, long-term Study 32 follow-up found that 88.5% of patients whose infections resolved with olorofim remained recurrence-free.
A FAERS-based review compared liver-related adverse-event reporting across five azole antifungals. Isavuconazole produced the weakest hepatobiliary signal, with a reporting odds ratio below those for voriconazole and posaconazole. Nevertheless, every azole in the analysis showed a meaningful liver-related reporting signal, prompting the researchers to recommend liver function monitoring for patients receiving any of these agents.
In separate long-term follow-up from Study 32, 88.5% of patients whose infections cleared on olorofim stayed free of recurrence. Olorofim is described as a first-in-class oral orotomide antifungal.
The findings may reassure clinicians considering isavuconazole for patients at liver risk, but because all azoles showed signals, monitoring could remain a practical safeguard. Patients with serious fungal infections and those with existing liver concerns may be most affected; better safety comparisons could inform treatment selection and follow-up, though the analysis cannot prove causality.